KUALA LUMPUR, March 14 (Bernama) -- Neuralstem Inc., a biopharmaceutical company focused on developing novel treatments for nervous system diseases, has highlighted the publication of a manuscript in Nature Medicine.
The manuscript shows that NSI-566, Neuralstem´s lead cell therapy candidate has provided meaningful improvement in forelimb function in a non-human primate model of acute spinal cord injury.
The manuscript entitled, ‘Restorative Effects of Human Neural Stem Cell Grafts on the Primate Spinal Cord´ involved a study to evaluate the potential benefits of transplanting NSI-566 into rhesus monkeys two weeks after they received a hemisection lesion of the cervical spinal cord.
In the study, NSI-566 was observed to extend hundreds of thousands of axons long distances from the graft site which appear to form synaptic connections with host neurons, including motor neuron populations.
It also hosts corticospinal axons that regenerate into the NSI-566 graft, leading to measurable improvement in forelimb function in injured animals.
The study was led by researchers at the University of California San Diego School of Medicine and builds on their previous work showing that grafted NSI-566 cells promote locomotor recovery in rats subjected to severe spinal cord injury.
Neuralstem´s chairman and chief executive officer, Richard Daly said the study strengthened their conviction that NSI-566 could potentially confer a benefit in patients with motor deficits from spinal injury.
"It also supports ongoing efforts in addressing conditions involving paralysis, such as amyotrophic lateral sclerosis and stroke, " he added.
-- BERNAMA
No comments:
Post a Comment